Merck Points To Keytruda, Zepatier Promise Coming Off Lackluster Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-seller Januvia had an off quarter, as Merck predicted previously, but the pharma pointed to substantial growth for its PD-1 inhibitor and its expectations of winning HCV market share with Zepatier.